Drug intelligence / Profile preview

MV140

Development stage: Phase 3
Lead developer: Inmunotek
Modality: Vaccines & Immunotherapeutics
Administration: Sublingual

Overview

MV140 (brand name Uromune) is a sublingual mucosal-based polybacterial vaccine developed by Inmunotek for the prevention of recurrent urinary tract infections (rUTIs). It consists of a suspension of four whole-cell heat-inactivated bacteria: *Escherichia coli*, *Klebsiella pneumoniae*, *Proteus vulgaris*, and *Enterococcus faecalis*. Administered as an oral spray, MV140 works by stimulating the innate immune system and inducing both systemic and local genitourinary immune responses, including the induction of trained immunity in the bladder. Clinical trials have demonstrated its efficacy in reducing UTI recurrence and antibiotic consumption while improving patient quality of life.

Brand names: Uromune
Other names: Uromune

Beyond the preview

Go deeper on MV140.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MV140.

Explore the full profile